In vitro tests have found that FEN1 deletion or gene inactivation could reverse cisplatin tolerance in ovarian cancer cells, while FEN1 small-molecule inhibition increased platinum sensitivity. The gene discussed is FEN1; the disease is ovarian carcinoma.